Paris

• A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended
  2023-505022-34-00 4 2024-03-27 Neoplasm malignant
• Safety and Immunogenicity of V116 in Children and Adolescents With Increased Risk for Pneumococcal Disease Ended
  2023-506236-32-00 5 2024-03-25 Pneumococcal disease
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder … Ended
  2022-502183-20-00 5 2024-02-26 Moderately to Severely Active Ulcerative Colitis
• A study to test how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis (ClairaflyTM) Ended
  2022-502835-21-00 4 2024-02-23 cystic fibrosis bronchiectasis
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or M … Ended
  2023-507321-42-00 1 2024-02-15 Myelodysplastic syndrome (MDS)
• Open-label study to evaluate metreleptin in children under 6 years of age with generalised lipodystrophy Ended
  2022-501781-22-00 5 2024-02-09 Generalised lipodystrophy
• A trial to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrop … Ended
  2023-504809-37-00 5 2024-02-07 Symptomatic Obstructive Hypertrophic Cardiomyopathy
• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• A Phase II/III Study of ABC008 to Determine Efficacy and Safety in IBM Ended
  2022-501925-19-00 10 2024-01-17 inclusion body myositis
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 Advanced or metastatic solid tumors
• A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of thr … Ended
  2023-506396-94-00 1 2024-01-08 Sarbecovirus diseases
• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended
  2023-503739-16-00 1 2023-12-20 Relapsed or refractory solid tumors or non-Hodgkin lymphoma
• COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit Ended
  2023-505108-52-00 5 2023-12-20 Intensive Care
• Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended
  2023-505350-18-00 4 2023-12-15 HIV Infections
• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 5 2023-12-11 ulcerative pyoderma gangrenosum
• Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) Ended
  2023-504153-12-00 4 2023-12-07 Advanced or Metastatic Solid Tumors
• A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim … Ended
  2023-503893-19-00 5 2023-12-06 HIV-1 infection
• Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors Ended
  2024-518411-19-00 9 2023-12-04 Advanced HER2-Expressing Solid Tumors.
• A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended
  2022-502799-22-00 4 2023-11-29 Knee osteoarthritis pain
• Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended
  2022-503137-66-00 5 2023-11-29 Human immunodeficiency virus (HIV)

Showing 1,921–1,944 of 2,286 trials